🇪🇺 Crixivan in European Union

EMA authorised Crixivan on 4 October 1996

Marketing authorisation

EMA — authorised 4 October 1996

  • Application: EMEA/H/C/000128
  • Marketing authorisation holder: Merck Sharp & Dohme B.V.
  • Local brand name: Crixivan
  • Indication: Crixivan is indicated in combination with antiretroviral nucleoside analogues for the treatment of HIV-1 infected adults.
  • Status: withdrawn

Read official source →

Crixivan in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Immunology approved in European Union

Frequently asked questions

Is Crixivan approved in European Union?

Yes. EMA authorised it on 4 October 1996.

Who is the marketing authorisation holder for Crixivan in European Union?

Merck Sharp & Dohme B.V. holds the EU marketing authorisation.